AstraZeneca’s press release announces that the FDA has approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) as the first and only single‑inhaler triple‑combination maintenance therapy for asthma in patients 12 years and older in the United States. Breztri, previously approved for COPD, combines an inhaled corticosteroid, a long‑acting beta2‑agonist, and a long‑acting muscarinic antagonist to improve lung function compared with standard dual therapies, with the approval supported by the large Phase III KALOS and LOGOS trials showing statistically significant and clinically meaningful lung function benefits and rapid onset of action without new safety signals. This approval is described as a pivotal advance for people living with asthma, expanding treatment options and potentially improving symptom control and quality of life.
INHALE Director, Dr. Njira Lugogo, contributed to the clinical research that helped bring new therapies like Breztri to patients, reflecting her broader commitment to advancing severe asthma care through ongoing clinical trials and innovation.
Read about it here: https://www.astrazeneca.com/media-centre/press-releases/2026/breztri-approved-in-the-us-for-asthma.html